Benfa Gong
Peking Union Medical College
38 Papers
26 Citations
Benfa Gong is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Medicine & Cytarabine. The author has an hindex of 5, co-authored 20 publications.
Chat about Author
Papers
A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood-brain Barrier in the Treatment of Patients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.
Xiaoyuan Gong,Le Li,Hui Wei,Bingcheng Liu,Chunlin Zhou,Guangji Zhang,Kaiqi Liu,Dong Lin,Benfa Gong,Shuning Wei,Yan Li,Yingchang Mi,Ying Wang,Jianxiang Wang +13 more
TL;DR: In this article, Dasatinib is a second-generation tyrosine kinase inhibitor with higher central nervous system penetration compared with imatinib and nilotinib in in vitro studies.
22
Clinical metagenomic sequencing of plasma microbial Cell-free DNA for febrile neutropenia in acute leukemia patients.
Sizhou Feng,Guan-Hua Rao,Xudong Wei,Rong Fu,Ming Hou,Yongping Song,Chunhui Xu,Peng Han,Benfa Gong,Xi Chen,Yihao Wang,Xiaoyuan Dong,Jianxiang Wang +12 more
TL;DR: In this paper , the diagnostic performance and clinical impact of metagenomic next-generation sequencing (mNGS) of plasma microbial cell-free DNA (mcfDNA) in febrile neutropenia (FN) patients were evaluated.
14
Benefit of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia.
Hui Wei,Chunlin Zhou,Dong Lin,Bingcheng Liu,Yan Li,Xingli Zhao,Shuning Wei,Benfa Gong,Kaiqi Liu,Xiaoyuan Gong,Yuntao Liu,Guangji Zhang,Jiayuan Chen,Junping Zhang,Jingjing Jin,Shaowei Qiu,Runxia Gu,Ying Wang,Yingchang Mi,Jianxiang Wang +19 more
TL;DR: Benefits of intermediate-dose cytarabine containing induction in molecular subgroups of acute myeloid leukemia and its application in clinical practice are described.
A short report of novel RARG-HNRNPM fusion gene in resembling acute promyelocytic leukemia
Yang Song,J. Hou,Li Wan,Kaiqi Liu,Chunlin Zhou,Shuning Wei,Guangji Zhang,Dong-Tsamn Lin,Yang Li,Qiuyun Fang,Yuntao Liu,Benfa Gong,Xiaoyuan Gong,Ying Wang,Hui Wei,Jianxiang Wang,Yingchang Mi +16 more
TL;DR: A 25-year-old female patient with a novel fusion gene RARG-HNRNPM as resembling APL was benefited from a combined chemotherapy homoharringtonine, cytarabine, and aclacinomycin (HAA) regimen with no relapse.
11
Efficacy of combination of venetoclax with azacitidine or chemotherapy in refractory/relapse acute leukemias of ambiguous lineage, not otherwise specified.
Kaiqi Liu,Yan Li,Shaowei Qiu,Chunlin Zhou,Shuning Wei,Dong Lin,Guangji Zhang,Hui Wei,Ying Wang,Bingcheng Liu,Xiaoyuan Gong,Qiuyun Fang,Yang Song,Huijun Wang,Chengwen Li,Qinghua Li,Lihua Wu,Benfa Gong,Yuntao Liu,Jianxiang Wang,Yingchang Mi +20 more
TL;DR: In this article, the authors reported 6 patients with acute leukemias of ambiguous lineage, not otherwise specified (ALAL-NOS) who were treated with venetoclax based treatment.